Key Highlights

  • Humana (NYSE:HUM) was up 14.82% in premarket trading on October 9, 2026 on a listed price of USD 387.12, extending a rally that began when CMS published its 2027 star ratings.
  • The main catalyst is a ratings upgrade: Humana's largest Medicare Advantage contract moved to 4 stars from 3.5 stars, restoring eligibility for federal quality Bonus payments.
  • The financial benefit is delayed. Reports say the bonus effect shows up mainly in 2028 revenue, because ratings published now drive payments for a later plan year.
  • Rival Alignment Healthcare moved the other way, falling about 23% premarket after its largest California contract slipped to 3.5 stars from 4, so ratings cut both ways.

What Moved Humana Shares

Humana (NYSE:HUM) was indicated up 14.82% in the October 9, 2026 premarket session, based on a listed price of USD 387.12 on the premarket screener. Published reports tie the move to the Centers for Medicare and Medicaid Services 2027 Star Ratings, released on October 8, 2026, in which the insurer's largest Medicare Advantage contract rose to 4 stars from 3.5 stars. Reports also described a gain of about 16.5% in the October 8 session, so the premarket figure and the daily figure overlap in time and should not be added together. Another premarket quote showed a smaller gain near 13.4%, which shows how fast indicated prices shift before the open. Every move here is a premarket or reported quote, not a closing price.

How Star Ratings Drive Revenue

CMS rates Medicare Advantage contracts from 1 to 5 stars using clinical outcomes, member experience and plan operations. Contracts rated 4 stars or higher qualify for quality bonus payments, which raise the federal funding an insurer receives per member. That makes a half-star move around the 4 star line unusually valuable: Humana (NYSE:HUM) regained eligibility on its biggest contract, while Alignment lost it on its biggest. Humana's own history shows the stakes. After its 2024 ratings fell, the share of members in plans rated 4 stars or better dropped from 94% to 25% for the following year, according to a published account. Bonus payments tied to the new ratings are reported to flow mainly into 2028.

Risks and What to Watch

The upgrade restores eligibility but does not guarantee earnings, and a rally of this size prices in a lot. Humana (NYSE:HUM) still faces medical cost trends, risk adjustment changes and annual rate notices that decide margins long before 2028 bonus dollars arrive. Investors should read the full contract-level ratings, since one large contract does not define the whole book, and watch the next Quarterly Report for cost commentary. Alignment Healthcare shows how concentrated membership magnifies a single rating decision. Premarket Volume was thin, 1,945 shares at the screener snapshot, so the indicated price can swing sharply at the open and should not be read as a settled valuation.

Where Things Stand

Humana (NYSE:HUM) is up in premarket because CMS lifted its largest Medicare Advantage contract to 4 stars from 3.5 stars, restoring eligibility for quality bonus payments, according to published reports on the October 8 ratings release. That is a real catalyst, but the payoff is mostly a 2028 story, and the stock had already risen about 16.5% on October 8. The balance of evidence points to better Earnings power, tempered by cost trends and the risk that much of the benefit is priced in. The next checkpoints are the contract-level ratings detail and the next earnings report.